Breakpoints cover image

#69 – IDWeek 2022 Recap: Practice Changing Publications – Midnights Edition

Breakpoints

00:00

Hepatitis D

Hep B surface antigen positive let's screen for Hep D and keep an eye out for future therapeutics in this space. The MIR 301 trial was phase three randomized open label parallel group multi center study patients were randomized to a couple of different dose soothing forms of blue levered type. In looking at the co primary endpoint of undetectable Hep D RNA and normalization of ALT levels, we did see benefit in the groups that did not delay treatment. Remember this study next up is Minh Mon during the treatment of Hep C with Sophospia vellpatosphere for 12 weeks.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app